Can't find Entyvio? Learn about the best alternatives for ulcerative colitis and Crohn's disease, including Humira, Stelara, Skyrizi, and Rinvoq.
If you've been prescribed Entyvio (Vedolizumab) for ulcerative colitis or Crohn's disease and you can't get it filled — whether due to supply issues, insurance denials, or cost — you may be wondering what your options are.
The good news is that there are several effective alternatives available in 2026. While no two biologics work exactly the same way, your gastroenterologist can help you find a treatment that manages your IBD effectively while you wait for Entyvio to become available, or as a long-term alternative.
Important: Never stop or switch your medication without talking to your doctor first. This article is for educational purposes and is not medical advice.
Entyvio is a biologic medication made by Takeda Pharmaceuticals. Its generic name is Vedolizumab, and it belongs to a class of drugs called integrin receptor antagonists.
What makes Entyvio unique is its gut-selective mechanism. It works by blocking a protein called integrin α4β7 on immune cells, preventing those cells from traveling to the gastrointestinal tract and causing inflammation. This targeted approach means Entyvio reduces inflammation in the gut without broadly suppressing the entire immune system.
Entyvio is FDA-approved for:
It's available as a 300 mg IV infusion (administered every 8 weeks after induction) and as a 108 mg subcutaneous injection via the Entyvio Pen (every 2 weeks for maintenance). For more details, read our full guide on what Entyvio is and how it's used.
There are several reasons patients look for alternatives to Entyvio:
Whatever the reason, it's important to work with your gastroenterologist to choose the right alternative based on your specific condition, treatment history, and overall health. You can also use Medfinder to search for medications in stock near you.
Humira is one of the most widely prescribed biologics in the world. It's a TNF-alpha inhibitor that works by blocking tumor necrosis factor, a protein that drives inflammation throughout the body.
Humira is a subcutaneous injection that patients can self-administer at home, typically every two weeks.
Stelara is an IL-12/23 inhibitor. It targets interleukins 12 and 23, proteins that play a key role in the inflammatory immune response in IBD.
Stelara starts with a single IV infusion for induction, followed by subcutaneous injections every 8 weeks for maintenance.
Skyrizi is a newer IL-23 inhibitor that specifically targets interleukin-23, one of the key drivers of gut inflammation in IBD.
Skyrizi begins with IV infusions for induction, then transitions to subcutaneous injections every 8 weeks for maintenance.
Rinvoq is a JAK inhibitor (Janus kinase inhibitor) — and notably, it's an oral medication, not an injection or infusion.
Rinvoq is taken as a once-daily pill. The typical dose is 45 mg daily during induction, then 15 mg or 30 mg daily for maintenance.
Choosing an Entyvio alternative is a decision you should make with your gastroenterologist. Key factors include:
If you can't fill your Entyvio prescription, you're not out of options. Humira (and its affordable biosimilars), Stelara, Skyrizi, and Rinvoq are all effective alternatives for managing ulcerative colitis and Crohn's disease. Each works through a different mechanism, so there's a good chance one of them will work well for you.
Before making any changes, talk to your gastroenterologist. And if you're still hoping to find Entyvio, try Medfinder to check real-time availability at specialty pharmacies near you.
Related reading:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
